In-depth coverage of the UK’s exit from the EU, and what it means to pharma and healthcare.
Parallel Trade 2018
Government must strike science R&D deal with EU, says ABPI
But BMA warns more must be done to prevent Brexit brain-drain.
Health and business secretaries commit to close working with EMA
How the UK’s exit from the EU may influence pharma companies’ decisions to stay or go.
Saratha Rajeswaran will lead government affairs team
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
March 14, 2017
Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.